These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 7720083

  • 1. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN, Casement KS, Arlinghaus RB, Sastry KJ.
    Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
    [Abstract] [Full Text] [Related]

  • 2. Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response.
    Nehete PN, Arlinghaus RB, Sastry KJ.
    Viral Immunol; 1994 Feb; 7(4):189-97. PubMed ID: 7576033
    [Abstract] [Full Text] [Related]

  • 3. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C, Golding B, Inman J, Blackburn R, Manischewitz J, Highet P, Golding H.
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS, Choi MJ, Kim TY, Cho SY, Cheong HS.
    Vaccine; 1999 Mar 17; 17(11-12):1540-8. PubMed ID: 10195791
    [Abstract] [Full Text] [Related]

  • 5. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.
    Layton GT, Harris SJ, Gearing AJ, Hill-Perkins M, Cole JS, Griffiths JC, Burns NR, Kingsman AJ, Adams SE.
    J Immunol; 1993 Jul 15; 151(2):1097-107. PubMed ID: 8335892
    [Abstract] [Full Text] [Related]

  • 6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 15; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 7. Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120.
    Sastry KJ, Nehete PN, Venkatnarayanan S, Morkowski J, Platsoucas CD, Arlinghaus RB.
    Virology; 1992 Jun 15; 188(2):502-9. PubMed ID: 1316670
    [Abstract] [Full Text] [Related]

  • 8. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
    Wagner R, Böltz T, Deml L, Modrow S, Wolf H.
    J Gen Virol; 1993 Jul 15; 74 ( Pt 7)():1261-9. PubMed ID: 7687647
    [Abstract] [Full Text] [Related]

  • 9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE, Abaitua F, Rodríguez D, Esteban M.
    Virus Res; 2004 Sep 15; 105(1):11-22. PubMed ID: 15325077
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1.
    Casement KS, Nehete PN, Arlinghaus RB, Sastry KJ.
    Virology; 1995 Aug 01; 211(1):261-7. PubMed ID: 7645219
    [Abstract] [Full Text] [Related]

  • 12. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A, Nielsen HV, Bryder K, Nielsen C, Machuca R, Bruun L, Hansen J, Buus S.
    Scand J Immunol; 1998 Apr 01; 47(4):289-95. PubMed ID: 9600309
    [Abstract] [Full Text] [Related]

  • 13. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF.
    Vaccine; 1997 Jun 01; 15(9):1001-7. PubMed ID: 9261947
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ.
    J Immunol; 1997 Jan 15; 158(2):834-41. PubMed ID: 8993001
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX, Cianciolo GJ, Staats HF, Scearce RM, Lapple DM, Stauffer SH, Thomasch JR, Pizzo SV, Montefiori DC, Hagen M, Eldridge J, Haynes BF.
    Vaccine; 2002 May 22; 20(17-18):2396-403. PubMed ID: 12009296
    [Abstract] [Full Text] [Related]

  • 19. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A, Hamajima K, Nakajima K, Kawamoto S, Phanuphak P.
    J Mol Recognit; 1993 Sep 22; 6(3):101-9. PubMed ID: 8060667
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.